Download possible relevant diagnosis codes for urothelial carcinoma

The following codes as of July 2021 are provided as a reference and may be relevant when billing for KEYTRUDA and its administration. Consult the relevant manual and/or other guidelines for a description of each code to determine the appropriateness of its use and for information on additional codes. Diagnosis codes should be selected only by a health care professional. You are solely responsible for determining the appropriate codes and for any action you take in billing.

When submitting a claim for KEYTRUDA, always verify coding requirements with the relevant payer. Coding requirements may vary by insurer or plan; please refer to the payer-specific policies to understand what may be covered.

Check with the relevant payer regarding guidance on which diagnoses they will recognize and the applicability of secondary codes. Health care professionals are solely responsible for selecting codes that appropriately reflect the patient’s diagnosis, the services rendered, and the applicable payers’ guidelines.

Providers should document the diagnosis with a sufficiently high degree of specificity based on the information available to enable the identification of the most appropriate code. Although CMS has said that an unspecified code may be appropriate in some cases, CMS has advised that you should always code with as much specificity as possible consistent with the clinical documentation.

Merck and its agents make no warranties concerning the accuracy or appropriateness of this information for your particular use given the frequent changes in public and private payer billing. Merck cautions that payer-coding requirements vary and can frequently change, so it is important to regularly check with each payer or, where applicable, the Medicare Administrative Contractor as to payer-specific requirements. The use of this information does not guarantee payment or that any payment received will cover your costs.


KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC):

  • who are not eligible for any platinum-containing chemotherapy, or
  • who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

FDA-Approved Dosing

The FDA-approved dose of KEYTRUDA is either 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks or 400 mg administered as an intravenous infusion over 30 minutes every 6 weeks, until disease progression or unacceptable toxicity, or up to 24 months.

KEYTRUDA is indicated for use at an additional recommended dosage of 400 mg every 6 weeks for all approved adult indications. This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Possible relevant diagnosis codes for urothelial carcinoma

Learn more about each diagnosis code and descriptor by selecting from the series options below.


C65: Malignant Neoplasm of Renal Pelvis5

The C65 series:

  • Includes: malignant neoplasm of pelviureteric junction, malignant neoplasm of renal calyces
C65.1 Malignant neoplasm of right renal pelvis
C65.2 Malignant neoplasm of left renal pelvis

C66: Malignant Neoplasm of Ureter5

The C66 series:

  • Excludes: malignant neoplasm of ureteric orifice of bladder
C66.1 Malignant neoplasm of right ureter
C66.2 Malignant neoplasm of left ureter

C67: Malignant Neoplasm of Bladder5

C67.0 Malignant neoplasm of trigone of bladder
C67.1 Malignant neoplasm of dome of bladder
C67.2 Malignant neoplasm of lateral wall of bladder
C67.3 Malignant neoplasm of anterior wall of bladder
C67.4 Malignant neoplasm of posterior wall of bladder
C67.5 Malignant neoplasm of bladder neck
  • Malignant neoplasm of internal urethral orifice
C67.6 Malignant neoplasm of ureteric orifice
C67.8 Malignant neoplasm of overlapping sites of bladder
C67.9 Malignant neoplasm of bladder, unspecified

C68: Malignant Neoplasm of Other and Unspecified Urinary Organs5

The C68 series:

  • Excludes: malignant neoplasm of female genitourinary tract not otherwise specified (NOS), malignant neoplasm of male genitourinary tract NOS
C68.0 Malignant neoplasm of urethra
  • Excludes: malignant neoplasm of urethral orifice of bladder
C68.8 Malignant neoplasm of overlapping sites of urinary organs
  • Primary malignant neoplasm of two or more contiguous sites of urinary organs whose point of origin cannot be determined